studies

992A AASLD ABSTRACTS HEPATOLOGY, October, 2015
sis.Conclusion: IL-2R and TGF-a were independent predictors
for significant fibrosis in CHB patients with normal or mildly
elevated ALT. An IL-2R and TGF-a based score, fib-index, was
superior to APRI, FIB-4 for the diagnosis of significant fibrosis.
Disclosures:
The following authors have nothing to disclose: Gui-Qiang Wang, Yong-Qiong
Deng, Hong Zhao
1603
Characterization of Nucleic acid testing reaction samples
and Occult Hepatitis B infection Among blood
donors in three cities of China
Xiaomei Wang, Xiumei Chi, Ruihong Wu, Xiuzhu Gao, Junqi
Niu; Hepatology, The First Hospital of Jilin University, Changchun,
China
Introduction. In China, HBV infection is common. With increasing
voluntary blood donation and the still-prevalent infectious
diseases in donors, we need to augment transfusion-transmitted
infections testing before use. Our study was aimed to compare
the seroprevalence of HBV, HCV and HIV among the
donors of Chineses tested by ELISA and nucleic acid testing
(NAT) . A variant of hepatitis B virus (HBV) having a specific
mutation within the S gene has been found in occult HBV infection
(OBI) . To know whether similar variants were involved in
blood donors, we analyzed 18 blood samples HBV S region
sequence. Materials and Methods. Enzyme linked immunosorbent
assay (ELISA) was used for detection of HBsAg, HBeAg,
anti-HBs, anti-HBe, anti-HBc,anti-HIV, and anti-HCV in all donor
serum. The blood samples which were negative on ELISA were
also subjected to NAT testing for HBV, HCV, and HIV. Nested
PCR were used to amplify the S regions and products were
sequenced and analyzed. Results. A total of 482370 donations
were tested in studied, NAT yielded 156 HBV-DNA-positive
donations in the HBsAg-negative (1:2365). NAT yielded 2
HIV-RNA-positive donations were p24 Ag reactive. There were
no NAT positive in anti-HCV negative donations. There were
no escape mutations observed in the S gene. Conclusion. In
regions with a high prevalence of HBV,there are likely to be
a significant number of OBI donations that can be identified
by NAT. Therefor, in order to provide safe blood, NAT should
be applied in blood centers for testing HBV.In 18 occult HBV
infections, HBV sequences lacked G145R and other escape
mutations in S region, which may be caused by wild-type HBV
strains.
Disclosures:
The following authors have nothing to disclose: Xiaomei Wang, Xiumei Chi,
Ruihong Wu, Xiuzhu Gao, Junqi Niu
1604
Baseline quantitative hepatitis B core antibodies can
predict HBV DNA and HBsAg seroclearance in treatment-naïve
HBeAg negative chronic hepatitis B patients
Hui-Han Hu 1 , Jessica Liu 1 , Chia-Lin Chang 1 , Chin-Lan Jen 1 , Mei-
Hsuan Lee 2 , Sheng-Nan Lu 3 , Li-Yu Wang 4 , San-Lin You 1 , Pei-Jer
Chen 5,6 , Hwai-I Yang 1 , Chien-Jen Chen 1,7 ; 1 Genomics Research
Center, Academia Sinica, Taipei, Taiwan; 2 Institute of Clinical
Medicine, National Yang-Ming University, Taipei, Taiwan;
3 Department of Gastroenterology, Chang-Gung Memorial Hospital,
Kaohsiung, Taiwan; 4 MacKay College of Medicine, Taipei,
Taiwan; 5 Division of Gastroenterology, Department of Internal
Medicine, National Taiwan University Hospital, Taipei, Taiwan;
6 National Taiwan University, Graduate Institute of Clinical Medicine,
Taipei, Taiwan; 7 Graduate Institute of Epidemiology and
Preventative Medicine, College of Public Health, National Taiwan
University, Taipei, Taiwan
Hepatitis B core antibody (anti-HBc) is one of the classical seromarkers
for HBV infection. Several lines of evidence showed
that among chronic hepatitis B (CHB) patients, quantitative
anti-HBc levels were strongly correlated with serum ALT levels,
suggesting that anti-HBc is a surrogate indicator of immune
activation. In addition, among treated HBeAg-seropositive CHB
patients, baseline quantitative anti-HBc levels were strong predictors
for treatment responses including HBeAg seroconversion.
Here, we investigated the impact of baseline quantitative
anti-HBc levels on spontaneous HBV DNA and HBsAg seroclearance
in treatment-naïve HBeAg negative CHB patients
from the REVEAL-HBV cohort (n=2503). Baseline anti-HBc levels
were assessed using a newly developed double-sandwich
anti-HBc immunoassay. HBV DNA and HBsAg levels were longitudinally
evaluated with repeated measurement in the longterm
follow-up samples. The associations of baseline anti-HBc
levels with HBV DNA and HBsAg seroclearance were assessed
by multivariate-adjusted Cox proportional hazard regression
models. The rate ratios (RR adj
) with 95% confidence intervals
(CI) were estimated. Baseline HBV DNA levels were significantly
and positively associated with increasing anti-HBc levels.
Mean log 10
(anti-HBc) levels were 2.82, 3.64, 3.95, 4.14,
and 4.29, respectively, for patients with HBV DNA levels of